-
Praeruptorin A Applied Research Workflows
2026-09-18
Build reproducible workflows around Praeruptorin A for ferroptosis, inflammatory-barrier injury, cardiomyopathy research, and tumor-cell invasion. This guide emphasizes dose selection, orthogonal readouts, formulation control, and pathway-level troubleshooting rather than single-marker conclusions.
-
EGFP mRNA m1Ψ: Calibrating Electroporation
2026-09-18
EGFP mRNA m1Ψ can function as more than a fluorescence control. This article presents a state-aware framework for separating RNA delivery, cell stress, translation, and functional antigen presentation during electroporation studies.
-
In Situ TIL Therapy via mRNA-LNP Delivery
2026-09-17
The ACS Nano study introduces an in situ tumor-infiltrating lymphocyte strategy that uses intratumoral lipid nanoparticles to deliver mRNA encoding a membrane-anchored anti-CD3 single-chain variable fragment. By engineering both tumor-associated macrophages and tumor cells, the approach promotes local polyclonal CD8+ TIL expansion and tumor-cell engagement, including in combination with anti-PD-1 therapy.
-
PreScission Protease Workflows for Native Proteins
2026-09-17
PreScission Protease enables sequence-specific fusion protein tag cleavage while preserving a low-temperature workflow suited to structurally sensitive targets. This article translates the Drosophila Keap1–lamin study into practical protein-production, interaction-assay, and troubleshooting strategies.
-
Mutational Landscapes of Multiple Myeloma Cell Lines
2026-09-16
Vikova and colleagues used whole-exome sequencing to define coding mutations across a heterogeneous panel of human multiple myeloma cell lines and connected genomic alterations with pathway activity and drug response. The resulting resource improves model selection for studies of myeloma progression, DNA repair, and therapeutic resistance while highlighting why cell-line genotype should be considered when interpreting pharmacological experiments.
-
GST Antioxidant Defense in Lambda-Cyhalothrin Resistance
2026-09-16
Dong and colleagues show that glutathione S-transferase activity is a functional component of lambda-cyhalothrin resistance in Megalurothrips usitatus, linking insecticide exposure to antioxidant protection rather than treating GST induction as a merely correlated response. Using RT-qPCR, biochemical measurements, pharmacological GST inhibition, and insecticide-sensitivity testing, the study demonstrates that weakening GST activity lowers antioxidant capacity and markedly increases insecticide susceptibility.
-
Light-Inducible RNA Release for Gene Therapy
2026-09-15
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses mRNA translation in darkness and permits therapeutic protein production under blue or ambient light. In mouse models, this translation-level switch regulated gene therapy for diet-induced obesity and retinal neovascular disease, highlighting a route toward on-demand control of long-acting genetic medicines.
-
SGI-1027 Induces Apoptosis in Huh7 Cells
2026-09-15
The 2018 study by Sun and colleagues examined how the DNA methyltransferase inhibitor SGI-1027 affects human hepatocellular carcinoma Huh7 cells. Its main contribution is evidence that SGI-1027 suppresses viability primarily through apoptosis, with changes in Bcl-2 and Bax consistent with mitochondrial pathway involvement rather than a measurable cell-cycle arrest.
-
Cy3 RNA Labeling Kit: Practical Workflow
2026-09-14
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides a defined in vitro transcription workflow for producing randomly Cy3-modified RNA probes for fluorescence-based research. It is suited to applications such as in situ hybridization and Northern blotting, but it is not intended for diagnostic, therapeutic, or medical use.
-
Copper–Hexetidine Synergy in Oral Streptococci
2026-09-14
Grytten, Scheie, and Giertsen demonstrated strong in vitro synergy between copper sulfate and hexetidine against Streptococcus sobrinus and Streptococcus sanguis, with fractional inhibitory concentration indices of 0.39–0.40. Their microdilution and growth-curve design provides a useful framework for evaluating combination antibacterial effects while also showing why planktonic oral-streptococcal findings should not be generalized directly to other organisms or infection models.
-
Actinomycin D Workflows for RNA Stability
2026-09-13
Actinomycin D provides a practical way to separate transcriptional input from RNA decay, making it useful for mRNA stability, transcriptional stress, and apoptosis studies. This guide translates those workflows to allergic-rhinitis models while clearly distinguishing established findings from assay recommendations.
-
SB203580: Mapping p38-AKT Resistance Networks
2026-09-12
SB203580 is a selective ATP-competitive p38 MAPK inhibitor with value beyond routine pathway blockade. This guide shows how to use it as a mechanistic probe alongside the HDAC8-PLCB1-AKT resistance framework described in a key MEK inhibition study.
-
Realgar Toxicity and the Liver–Brain Ornithine Axis
2026-09-11
The reference study links realgar-derived arsenic toxicity to a liver–brain mechanism in which hepatic OTC inhibition elevates ornithine and intensifies ZBTB7A-mediated suppression of astrocyte glycolysis. Its integrated animal, cellular, single-cell transcriptomic, metabolomic, behavioral, and histopathological evidence identifies ornithine regulation and astrocyte energy failure as connected features of central nervous system injury.
-
Canagliflozin: An Orthogonal Assay Control
2026-09-11
Canagliflozin hemihydrate is more than an SGLT2 tool for glucose metabolism research. This article explains how its negative result in a drug-sensitized yeast mTOR screen can sharpen pathway controls, assay interpretation, and experimental boundaries.
-
Carvedilol Phosphate in IRI Research
2026-09-10
Carvedilol Phosphate is a non-selective beta blocker research reagent with additional alpha-1 blocking activity. Its defined salt form, solvent profile, and storage requirements support controlled cardiovascular pharmacology research and hypothesis-driven ischemia–reperfusion injury studies.